July 14 (Reuters) - Gilead Sciences Inc will increase its stake in Galapagos NV and gain rights outside Europe to the Belgian-Dutch biotech firm’s treatments in development in a $5.1 billion deal, the Wall Street Journal reported on Sunday.
U.S. drugmaker Gilead will invest $1.1 billion, or 140.59 euros ($158.43) per share to increase its stake in Galapagos to 22% from 12.3%, and make a separate $3.95 billion payment to Galapagos, WSJ said.
The terms of the deal, including the research collaboration, are set to be announced on Sunday, the Journal added here.
$1 = 0.8874 euros Reporting by Ismail Shakil in Bengaluru, Editing by Rosalba O’Brien
Our Standards: The Thomson Reuters Trust Principles.